Related Experiment Video
Updated: Dec 27, 2025
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
IL-19 as a Biomarker for the Severity of Acute Myocardial Infarction
Liping Qi1, Jianwei Zhang2, Kui Wu3
1Department of Cardiology, The Second Clinical Center, Chinese PLA General Hospital, Beijing, China.
Insights
Interleukin-19 (IL-19) levels significantly increase in acute myocardial infarction (STEMI) patients, correlating with disease severity. Treatments like percutaneous coronary intervention (PCI) help reduce IL-19 levels, suggesting its potential as a therapeutic target.
Area of Science:
- Cardiology
- Immunology
- Biochemistry
Background:
- Interleukin-19 (IL-19) involvement in coronary artery disease and atherosclerosis is known.
- IL-19 expression in myocardial infarction (MI) remains poorly understood.
- This study investigates IL-19 dynamics in acute ST-segment elevation myocardial infarction (STEMI).
Purpose of the Study:
- To detect and analyze the dynamic changes in circulating IL-19 levels in STEMI patients.
- To compare IL-19 expression in STEMI patients versus chest pain syndrome (CPS) patients.
- To assess the impact of treatments on IL-19 levels in STEMI.
Main Methods:
- Plasma IL-19 levels and IL-19 mRNA in peripheral blood mononuclear cells (PBMCs) were measured.
- Measurements were taken on admission and at 1, 3, 7, and 14 days post-treatment.
- Correlations with cardiac biomarkers (cTnI, NT-proBNP, CRP) and LVEF were analyzed.
Main Results:
- IL-19 levels and mRNA expression were significantly elevated in STEMI patients, peaking at 1 day.
- Treatments, especially emergency PCI, markedly reduced IL-19 levels and promoted recovery.
- IL-19 levels positively correlated with cTnI, NT-proBNP, CRP, and LVEF in STEMI patients.
Conclusions:
- IL-19 levels correlate with the severity of acute myocardial infarction.
- IL-19 may represent a novel target for clinical intervention in myocardial infarction.
- Further research into IL-19's role in MI pathogenesis and treatment is warranted.
Background:
Interleukin-19 (IL-19) has been shown to be involved in coronary artery diseases and atherosclerosis, while its expression in myocardial infarction is poorly understood. In this study, the dynamic increase in circulating IL-19 in acute ST-segment elevation myocardial infarction (STEMI) patients was detected.
Method:
Both plasma IL-19 levels and IL-19 mRNA expression in peripheral blood mononuclear cells (PBMCs) from STEMI patients and chest pain syndrome (CPS) patients were detected at different time points, including 1 d, 3 d, 7 d and 14 d after treatment and on admission.
Results:
Compared with the CPS patients, IL-19 levels and IL-19 gene expression were significantly increased in STEMI patients and peaked at 1 d. From 1-14 d, refocusing treatment, including emergency percutaneous coronary intervention (PCI) and thrombolysis, markedly reduced IL-19 expression and promoted its recovery; of the treatments, the effect of emergency PCI was most significant. In addition, similar trends were also observed with cTnI, NT-proBNP and C-reactive protein (CRP) levels. Furthermore, correlation analysis showed that IL-19 levels were positively correlated with cTnI, NT-proBNP, CRP levels and left ventricular ejection fraction (LVEF) in STEMI patients.
Conclusions:
IL-19 is correlated with the severity of acute myocardial infarction, which may be a new idea for the clinical treatment of myocardial infarction.
More Related Videos
10:12A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
Published on: August 8, 2013
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Related Concept Videos
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations